In case long-standing tensions might erupt into violence in Israel, Given has set up a manufacturing facility in Ireland to take over production with minimal disruption to physicians and hospitals.
Given has focused more attention on Japan--a market with greater incidence of GI ailments--and we anticipate this geographic region will play a key role in driving Given's growth.
With more than 25 million GI imaging procedures taking place annually across the globe, there's plenty of room for Given to capture share from traditional endoscopy and X-ray that dominate the field. Read more
Given's future profitability depends greatly on whether it can bring operational costs down much faster and further than it has in the past.
The PillCam ESO remains at a disadvantage to traditional upper endoscopies because it doesn't allow the physician to take any biopsy samples during the procedure.
The initial diagnostic indication for PillCam COLON in the U.S. will be limited to patients who are contraindicated for traditional camera colonoscopy--a patient pool we estimate at 2 million, which is far smaller than the total patient pool for traditional colonoscopy. Read more
We think Given's stewardship is standard. After several years of considerable management turnover, Homi Shamir stepped into the president and CEO roles in spring 2006. We think Shamir brings the right type of global imaging experience from his previous Read more
Based in Israel, Given Imaging develops, manufactures, and markets patient-friendly systems for diagnosing gastrointestinal disorders. The firm's main product is the small-bowel Read more
ACA 'Fix' Won't Cause Breakdown for Insurers Watch more